Universal, off-the-shelf cell therapy
Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.
Healthy
Mononuclear cells collected
from healthy donors
Cells modification
Modified through a proprietary
process to express “eat me”
signal (PtdSer) on their surface,
while maintaining an intact membrane
Patient
Triggering engulfment into
macrophages via binding to BAI,
TIM4, and stabilin 2, annexin V
Activated macrophage
Homeostatic macrophage
Clinical focus
Our clinical development programs focus on treating solid tumors, sepsis and COVID-19. Our most advanced product candidate, Allocetra™ has demonstrated positive safety, tolerability and efficacy in several clinical trials. In addition to our ongoing late-stage clinical trials in sepsis and COVID-19, we plan on initiating clinical trials of Allocetra™ in solid cancer patients during 2022.
Extensive pre-clinical data
Rich pipeline of registration studies targeting conditional marketing approval
3 primary indications
Recent Publications
2010 | iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kB dependent blockade,
Gil Amarilyo, Dror Mevorach, et al., European Journal of Immunology
